Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors

INTRODUCTION: c-MET is an important therapeutic target for various cancers; however, the People’s Republic of China currently retails only one specific c-MET inhibitor. Our preclinical study has revealed the high selectivity of HS-10241 to suppress c-MET. This phase 1 study aims to evaluate the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xiaorong, Li, Xingya, Chen, Jianhua, Ma, Shenglin, Mu, Deguang, Hu, Jie, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943892/
https://www.ncbi.nlm.nih.gov/pubmed/36846572
http://dx.doi.org/10.1016/j.jtocrr.2022.100449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943892/
https://www.ncbi.nlm.nih.gov/pubmed/36846572
http://dx.doi.org/10.1016/j.jtocrr.2022.100449

Ejemplares similares